Table 3.

Therapeutic targets with the greatest translational potential in ENKTL.

Therapeutic Targets or Signaling Pathway	Clinical Significance for Therapeutics	Reference
JAK-3	JAK-3 inhibition is shown to have potent anti-tumor activity in pre-clinical models. Clinical trials evaluating JAK inhibitors in ENKTL are in progress.	Sim et al. 2017 [77] Narisimagi et al. 2017 [79]
STAT-3	STAT-3 mutant ENKTL are sensitive to STAT-3 inhibition in vitro.	Sim et al. 2017 [77]
NF-kB	NF-kB upregulation is an important event in ENKTL pathogenesis. Bortezomib is being evaluated in early phase clinical trials.	Tang et al. 2016 [49]
CD38	CD38 is upregulated in ENKTL. Daratumumab has good in vitro efficacy and one case report documenting complete response.	Mustafa et al. 2017 [124] Hari et al. 2016 [125]
PD-1	PD-L1 is upregulated in ENKTL. Early clinical trials show potent single agent activity of anti PD-1 therapy in relapsed, refractory ENKTL.	Kwong et al. 2017 [116]